We serve D-Tyrosine CAS:556-02-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
D-Tyrosine
CAS RN: 556-02-5
| Solubility in 3M-HCl | Colorless & clear (c=5) |
| Specific rotation [α]D20 | +11.2°～+12.3°(c= 5, 1M-HCl) |
| Loss on drying | Not more than 0.3% |
| Residue on ignition (as sulfate) | Not more than 0.1% |
| Chloride (Cl) | Not more than 0.03% |
| Sulfate (SO4) | Not more than 0.03% |
| Heavy metals (as Pb) | Not more than 10ppm |
| Iron (Fe) | Not more than 10ppm |
| Ammonium (NH4) | Not more than 0.02% |
| Arsenic (As2O3) | Not more than 1ppm |
| Other amino acids | Not detected by T.L.C.(The spotted amount, 10μg) |
| Assay | 98.5%～101.0% |
| L-Isomer | Not more than 0.5% |
Contact us for information like D-Tyrosine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,D-Tyr physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,D-Tyrosine Use and application,D-Tyrosine technical grade,usp/ep/jp grade.
Related News: “Ultimately, this is a public health decision,” she said, adding that the restrictions were precautionary measures to keep the country virus-free and contain the worldwide outbreak.Triethoxyoctylsilane manufacturer However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.Hydroxy Tyrosol α-Acetate supplier However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.3,5-Dimethylbenzoyl Chloride vendor Global Times reported that local officials had been putting up slogans in an effort to get communities to stay at home during the epidemic and to avoid people gathering together to slow and prevent the spread of the coronavirus.“We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”
